Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 19;19(1):977.
doi: 10.1186/s12913-019-4588-x.

THRIVE Study Protocol: A Randomized Controlled Trial Evaluating a Web-Based App and Tailored Messages to Improve Adherence to Adjuvant Endocrine Therapy Among Women With Breast Cancer

Affiliations
Free PMC article

THRIVE Study Protocol: A Randomized Controlled Trial Evaluating a Web-Based App and Tailored Messages to Improve Adherence to Adjuvant Endocrine Therapy Among Women With Breast Cancer

Andrew J Paladino et al. BMC Health Serv Res. .
Free PMC article

Abstract

Background: Long-term use of adjuvant endocrine therapy (AET) among women with early-stage, hormone receptor-positive breast cancer significantly reduces the risk of hospitalizations, cancer recurrence, and mortality. AET is associated with adverse symptoms that often result in poor adherence. A web-enabled app offers a novel way to communicate and manage symptoms for women on AET. In a region with significant racial disparities in breast cancer outcomes, our study tests the impact of a web-enabled app that collects and transmits patient-reported symptoms to healthcare teams to facilitate timely and responsive symptom management on medication adherence.

Methods: In this randomized controlled trial, we randomize 300 patients initiating AET to one of three arms: 1) an "App" group (n = 100) that receives weekly reminders to use the THRIVE study app; 2) an "App+Feedback" group (n = 100) that receives weekly reminders and tailored feedback based on their use of the app; or 3) a "Usual Care" group (n = 100) that receives usual care only. Participants are stratified by race: 50% White and 50% Black. The duration of the intervention is six months following enrollment, and outcomes are assessed at 12-months. The primary outcome is adherence, which is captured using an electronic monitoring pillbox. Secondary outcomes include symptom burden, quality of life, self-efficacy for managing symptoms, and healthcare costs. We also evaluate the impact of the intervention on racial disparities in adherence. Data are derived from three sources: electronic health record data to capture treatment changes, healthcare utilization, and health outcomes; self-report survey data related to adherence, symptom burden, and quality of life; and an electronic medication monitoring device that captures adherence.

Discussion: A successful web-enabled intervention could be disseminated across systems, conditions, and populations. By evaluating the impact of this intervention on a comprehensive set of measures, including AET adherence, patient outcomes, and costs, our study will provide valuable and actionable results for providers, policy makers, and insurers who strive to achieve the "Triple Aim" - reduce costs while improving health outcomes and the patient care experience.

Trial registration: NCT03592771. Prospectively registered on July 19, 2018.

Keywords: Adjuvant endocrine therapy; Breast cancer; Medication adherence; Mhealth; Patient-reported outcomes; Quality of life; Randomized controlled trial.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Conceptual Framework Guiding THRIVE Intervention
Fig. 2
Fig. 2
Patient flow through the RCT
Fig. 3
Fig. 3
Screenshot of App Adherence and Symptom Questions
Fig. 4
Fig. 4
Screenshot of Free Text and Body Map
Fig. 5
Fig. 5
Screenshots of tailored app feedback messages

Similar articles

See all similar articles

References

    1. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42. doi: 10.3322/caac.21320. - DOI - PubMed
    1. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537. doi: 10.1007/s10549-010-1132-4. - DOI - PMC - PubMed
    1. Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA-Cancer J Clin. 2009;59(1):56–66. doi: 10.3322/caac.20004. - DOI - PubMed
    1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med. 2005;353(17):1784–1792. doi: 10.1056/NEJMoa050518. - DOI - PubMed
    1. Group EBCTC Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–1467. doi: 10.1016/S0140-6736(97)11423-4. - DOI - PubMed

Publication types

MeSH terms

Associated data

Feedback